Is the use of warfarin becoming obsolete?

Is the use of warfarin becoming obsolete?

Bibliographic Details
Main Authors:	Tarek Haykal, Smit S. Deliwala, Thomas L. Ortel
Format:	Article
Language:	English
Published:	Greater Baltimore Medical Center 2021-05-01
Series:	Journal of Community Hospital Internal Medicine Perspectives
Subjects:	vte thromboembolism noac doac
Online Access:	http://dx.doi.org/10.1080/20009666.2021.1918474

Similar Items

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
by: Alexander T. Cohen, et al.
Published: (2018-05-01)

Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
by: Anthony Chan, et al.
Published: (2018-11-01)

Reply: Pulmonary thromboembolism in an emergency hospital: Are our patients different?
by: Ioannou Petros
Published: (2018-03-01)

Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis
by: Tarun Dalia, et al.
Published: (2021-02-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01)

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review
by: Tomasz Górnicki, et al.
Published: (2023-05-01)

Venous thromboembolic complications in lymphoma patients
by: Otašević Vladimir, et al.
Published: (2020-01-01)

European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism
by: Carter Patrice, et al.
Published: (2024-03-01)

Review of Medical Therapies for the Management of Pulmonary Embolism
by: Ladan Panahi, et al.
Published: (2021-01-01)

Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study
by: Irene Scala, et al.
Published: (2023-11-01)

Direct Oral Anticoagulants and Timing of Hip Fracture Surgery
by: Seth M. Tarrant, et al.
Published: (2020-07-01)

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
by: John Castle, et al.
Published: (2020-08-01)

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
by: Zhi-Yan Liu, et al.
Published: (2022-03-01)

Plasma Drug Values of DOACs in Patients Presenting with Gastrointestinal Bleeding: A Prospective Observational Study
by: Dorotea Bozic, et al.
Published: (2023-08-01)

Review of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty
by: Jordan Etscheidt, et al.
Published: (2020-03-01)

Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
by: Dandan Li, et al.
Published: (2022-12-01)

Clinical epidemiology of venous thromboembolic disease: An institutional registry
by: Mohammed AlSheef, et al.
Published: (2022-07-01)

Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis
by: Yi-Dan Yan, et al.
Published: (2020-11-01)

Management of Traumatic Brain Injury in Patients with DOAC Therapy–Are the “New” Oral Anticoagulants Really Safer?
by: Anna Antoni, et al.
Published: (2022-10-01)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
by: Januar Wibawa Martha, et al.
Published: (2021-12-01)

Use of direct oral anticoagulants in hematologic malignancies
by: Ilona Leviatan, et al.
Published: (2023-12-01)

Clinical overview of venous thromboembolism
by: Gustav Schellack, et al.
Published: (2016-01-01)

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA
by: Alpesh Amin, et al.
Published: (2019-01-01)

Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center
by: Alidoost M, et al.
Published: (2021-05-01)

Venous Thromboembolism in Hospitalized Melanoma Patients: Analysis from the National Inpatient Sample Database
by: Alhasson H, et al.
Published: (2021-11-01)

Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs)
by: Vasilios Perifanis, et al.
Published: (2021-12-01)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
by: Heike Schwarb, et al.
Published: (2016-03-01)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023-02-01)

Rates of Intracranial Hemorrhage in Mild Head Trauma Patients Presenting to Emergency Department and Their Management: A Comparison of Direct Oral Anticoagulant Drugs with Vitamin K Antagonists
by: Gabriele Savioli, et al.
Published: (2020-06-01)

Assessment of the Effect on Thromboprophylaxis with Multifaceted Quality Improvement Intervention based on Clinical Decision Support System in Hospitalized Patients: A Pilot Study
by: Qian Gao, et al.
Published: (2022-08-01)

A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals
by: Imad Hajj, et al.
Published: (2021-02-01)

SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP
by: Alessandro Laganà, et al.
Published: (2024-02-01)

Direct oral anticoagulants for the treatment of Cancer-Associated Thrombosis
by: Łukasz Ledziński, et al.
Published: (2021-09-01)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
by: Emile Abimana, et al.
Published: (2022-03-01)

Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center
by: Ghazwa B. Korayem, et al.
Published: (2021-05-01)

Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome
by: Rasha Kaddoura, et al.
Published: (2023-06-01)

Safety profile of outpatient diagnostic catheterization procedures in patients under direct-acting oral anticoagulants
by: Cristina Ramírez Guijarro, et al.
Published: (2019-08-01)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
by: Ke-Xin Sun, et al.
Published: (2021-10-01)

Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?
by: Krishnan Shyamkumar, et al.
Published: (2021-01-01)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
by: Caroti Caroti, et al.
Published: (2023-07-01)